Plasma kallistatin levels in patients with COVID-19
Öz
Purpose: The aim of this study was to evaluate kallistatin levels in patients diagnosed with COVID-19 and compare them with healthy controls.
Materials and Methods: A total of 40 patients diagnosed with COVID-19, and 45 healthy controls were included in the study. The patient group was divided into 2 groups: patients treated in the service (n:20) and patients treated in the intensive care unit (n:20). Kallistatin levels were measured using the ELISA method.
Results: There was a significant difference in kallistatin levels between the patient group (n:40) and the control group (n:45). There was no significant difference in kallistatin between COVID-19 patients treated in the service and those treated in the intensive care unit. We found that the AUC for kallistatin was 0.856 in the ROC analysis performed between the patient and control groups. When comparing service and ICU patients in terms of laboratory parameters, there was a significant difference between the groups due to elevated potassium, AST, creatinine, ferritin, HGB and LDH in ICU patients.
Conclusion: As a result, kallistatin levels were significantly higher in the patient group than in the control group. Comprehensive studies with more patients are needed to understand whether kallistatin is elevated in COVID-19 patients due to the effects of COVID-19 or to eliminate oxidative stress.
Anahtar Kelimeler
Destekleyen Kurum
This research is financially supported by the Scientific and Technological Research Council of Turkey (TUBITAK)
Proje Numarası
Grant/Award Number: BIDEP-2209A Number: 1919B012109027.
Kaynakça
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
- Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int J Antimicrob Agents. 2020;55:105951.
- Cecchini R, Cecchini AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med Hypotheses. 2020;143:110102.
- Popadic V, Klasnja S, Milic N, Rajovic N, Aleksic A, Milenkovic M et al. Predictors of mortality in critically ill COVID-19 patients demanding high oxygen flow: A thin linebetween inflammation, cytokine storm, and coagulopathy. Oxid Med Cell Longev. 2021;20:6648199.
- Lang M, Som A, Carey D, Reid N, Mendoza DP, Flores EJ et al. Pulmonary vascular manifestations of COVID-19 pneumonia. Radiol Cardiothorac Imaging. 2020;43:e200277.
- Yucel K, Fuat Gurbuz A. Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients. Horm Mol Biol Clin Investig. 2022;43:415-20.
- Chao J, Li P, Chao L. Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem. 2017;398:1309-17.
- Chao J, Guo Y, Chao L. Protective role of endogenous kallistatin in vascular injury and senescence by inhibiting oxidative stress and inflammation. Oxid Med Cell Longev. 2018;2018:4138560.
- Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, Chao J. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol. 2012;303:1230-8.
- Wang G, Zou J, Yu X, Yin S, Tang C. The antiatherogenic function of kallistatin and its potential mechanism. Acta Biochim Biophys Sin (Shanghai). 2020;52:583-9.
